Salipro Biotech AB announced that it has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target. The collaboration brings together Salipro Biotech's unique expertise in developing stable antigens of GPCRs, ion channels and transporters via its proprietary Salipro® platform with Sanofi's discovery programs to identify biologics with the desired therapeutic properties against a selected target.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
89.97 EUR | -0.52% |
|
-0.90% | +0.23% |
03:05pm | SANOFI : Berenberg reiterates its Buy rating | ZD |
12:25pm | SANOFI : JP Morgan remains Neutral | ZD |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.23% | 121B | |
+56.37% | 816B | |
+39.48% | 634B | |
-7.46% | 351B | |
+16.10% | 323B | |
+6.99% | 293B | |
+13.32% | 238B | |
+0.82% | 222B | |
+13.35% | 218B | |
+8.18% | 167B |
- Stock Market
- Equities
- SAN Stock
- News Sanofi
- Salipro Biotech Enters into Collaboration and License Agreement with Sanofi to Advance Discovery Programs